Minimal residual disease-directed preemptive treatment with azacitidine in patients with NPM1-mutant acute myeloid leukemia and molecular relapse

Haematologica. 2011 Oct;96(10):1568-70. doi: 10.3324/haematol.2011.044388. Epub 2011 Jul 12.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antimetabolites, Antineoplastic / therapeutic use*
  • Azacitidine / therapeutic use*
  • Humans
  • Leukemia, Myeloid, Acute / drug therapy*
  • Leukemia, Myeloid, Acute / genetics*
  • Mutation*
  • Neoplasm, Residual
  • Nuclear Proteins / genetics*
  • Nucleophosmin
  • Recurrence
  • Treatment Outcome

Substances

  • Antimetabolites, Antineoplastic
  • NPM1 protein, human
  • Nuclear Proteins
  • Nucleophosmin
  • Azacitidine